Synchronicity Pharma

Synchronicity Pharma is a private, preclinical-stage biotech translating foundational circadian biology research into novel therapeutics. Its pipeline targets two distinct areas: microsatellite-stable colorectal cancer (MSS CRC) and sleep disturbances in pediatric autism spectrum disorder (ASD). The company is led by an experienced management team and guided by a world-class scientific advisory board, including luminaries in circadian science like Dr. Steve Kay and Dr. Joseph Takahashi. Its strategy hinges on modulating protein-protein interactions within the circadian clock machinery to address diseases with high unmet need.

A small molecule drug discovery platform targeting protein-protein interactions within the core circadian clock machinery to modulate biological timing for therapeutic effect in cancer and neuropsychiatric disorders.

The competitive landscape for circadian-targeted therapeutics is currently sparse but emerging. A few other biotechs (e.g., Ligand Pharmaceuticals' Viking Therapeutics spin-off has explored circadian metabolic drugs) and academic groups are exploring similar biology. Synchronicity's differentiation lies in its exclusive focus on clock PPIs for oncology/neuropsychiatry and its unparalleled scientific advisory board. It faces indirect competition from standard-of-care therapies in both indications.